Abstract: The present invention is related to antiviral compositions comprising long-chain aliphatic compounds in combination with a nucleoside analog or phosphonoformic acid, in a pharmaceutically acceptable carrier. Methods for treating viral infections using such compositions are also disclosed.

Abstract: This invention relates to topical therapeutic preparations and methods for treating viral and inflammatory diseases and for reducing the pain of topical inflammation of skin and mucous membranes. The preparations include creams containing n-docosanol.

Abstract: The present invention is related to antiviral compositions comprising long-chain aliphatic compounds in combination with a nucleoside analog or phosphonoformic acid, in a pharmaceutically acceptable carrier. Methods for treating viral infections using such compositions are also disclosed.

Abstract: The present invention is related to antiviral compositions comprising long-chain aliphatic compounds in combination with a nucleoside analog or phosphonoformic acid, in a pharmaceutically acceptable carrier. Methods for treating viral infections using such compositions are also disclosed.

Abstract: A method is disclosed for treating a benign or malignant hyperproliferative skin lesion, comprising topically administering a C18 to C20 aliphatic alcohol to the skin lesion in a pharmaceutically acceptable carrier.

Abstract: The invention provides an IgE and antigen-specific screening assay for use in identifying agents which suppress the IgE mediated immune response to antigen. The assay is performed in vivo in animals which hyper respond to antigen by producing exaggerated levels of IgE. The animals are sensitized to an antigen during a specific window of sensitivity which closes a day after the animal has been treated to produce the IgE hyper responsive phenotype. The screening assay is performed in the animals by treating them with a candidate IgE suppressor agent in conjunction with further immunization made after closure of the window of sensitivity defined by the invention. Positive results (indicating that the candidate agent has IgE suppressive activity) are obtained in the assay through measurement of a decline in antigen-specific IgE in the animal following its treatment with the candidate agent.

Abstract: Therapeutic compositions including a nonionic surfactant combined with long chain fatty acids, alkanes, amides or mono-unsaturated alcohols, particularly stearyl alcohol, erucyl alcohol, brassidyl alcohol, arachidyl alcohol, n-docosane, n-docosanoic acid, erucamide and stearic acid, or mixtures thereof, as active ingredients are disclosed. Methods of preventing or treating viral infections, treating skin or membrane inflammation or inhibiting cell proliferation using such compositions are disclosed.

Abstract: A method for treating a benign or malignant hyperproliferative skin lesion, comprising topically administering a C18 to C26 aliphatic alcohol to the skin lesion in a pharmaceutically acceptable carrier.

Abstract: A stable, efficacious therapeutic cream wherein a principal therapeutic compounds are one or more C-20 to C-28 long chain aliphatic alcohols, of which n-docosanol is exemplary, comprising sucrose cocoate, sucrose stearates or sucrose distearate, or mixtures thereof, is disclosed.

Abstract: A method of arthritis and other inflammatory diseases in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal to be treated a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier is disclosed.

Abstract: A method of arthritis and other inflammatory diseases in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal to be treated a composition consisting essentially of at least one C-27 to C-32 aliphatic alcohol in a physiologically compatible carrier is disclosed.

Abstract: Systemic antiviral treatment using a narrow class of aliphatic straight-chain saturated monohydric alcohols which have from 20 to 26, preferably 22 to 26, carbons in the chain in physiologically compatible compositions for injection or trans-mucus membrane introduction into humans and other animals is disclosed.

Abstract: Systemic antiviral treatment using a narrow class of aliphatic straight-chain saturated monohydric alcohols which have from 27 to 32 carbons in the chain in physiologically compatible compositions for injection or trans-mucus membrance introduction into humans and other mammals is disclosed.

Abstract: Receptor blocking technology using proteins conjugated to polymers of D-glutamic acid and D-lysine for treatment of antibody-mediated autoimmune disease, membrane and tumor disorders is disclosed.

Abstract: Receptor blocking technology using proteins conjugated to polymers of D-glutamic acid and D-lysine for treatment of antibody-mediated autoimmune disease, membrane and tumor disorders is disclosed.

Abstract: Receptor blocking technology using proteins conjugated to polymers of D-glutamic acid and D-lysine for treatment of antibody-mediated autoimmune disease, membrane and tumor disorders is disclosed.

Abstract: A method and apparatus for conducting specific binding pair assays, such as immunoassays, is described. A porous membrane capable of non-bibulous lateral flow is used as assay substrate; a member of the binding pair is affixed in an indicator zone defined in the substrate. The sample is applied at a position distant from the indicator zone and permitted to flow laterally through the zone; any analyte in the sample is complexed by the affixed specific binding member, and detected. A novel method of detection employs entrapment of observable particle in the complex. Blood is a particularly preferred sample as the red blood cells can be used as the observable particles for detection of the complex.

Abstract: A method treating virus-induced and inflammatory diseases of skin and membranes in humans or animals, comprising application of a composition consisting of one or more of the aliphatic alcohols docosanol, tetracosanol and hexacosanol in a physiologically compatible carrier is disclosed.

Abstract: Human chorionic gonadotropin (HCG) is detected by enzyme immunoassay by bonding biotinylated antibody to an avidin coupled paper disc, reacting the antibody on the disc with the solution suspected of containing HCG, and determining the amount of HCG on the disc by enzymatic assay detection techniques.

Abstract: Immunosuppressive agents which are conjugates of an antigen linked to a D glutamic acid:D-lysine copolymer are disclosed. Also disclosed are methods of preparing the conjugates and therapeutic methods for inducing immunological tolerance to antigens.